Overall, the immunosuppressive effects of IDO make it an appealing therapeutic target, and efforts to block this pathway have led to the development of IDO inhibitors that are currently undergoing clinical testing in various types of malignancy including AML (clinicaltrials.gov identifier: 02835729) (88). This evidence concerns the gene IDO1 and acute myeloid leukemia.